Abstract

Morbidity and mortality in those with heart failure (HF) remain high,so effective therapies aimed at reducing HF burden are needed. Anovel combination therapy containing sacubitril, a neprilysin inhibitor,and valsartan (Entresto—Novartis) received FDA approval to reducethe risk of cardiovascular death and HF hospitalization in patients withHF with a reduced ejection fraction.

Full Text

Published Version

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.